Phase 3 Readout~month

Phase 3 Topline: A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy a

Name: Phase 3 Topline: A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy a
Start: 2026-10-01

October 1, 2026

Company: Amylyx Pharmaceuticals, Inc. (AMLX)
Drug: post-bariatric
Indication: Post Bariatric Hypoglycemia

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start Free Full Calendar

Phase 3 Topline: A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy a — AMLX Phase 3 Readout | BioSniper